RIGL News and Press, Rigel Pharmaceuticals Inc. From 08/05/25

Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update PR Newswire Second quarter 2025 total revenue of approximately $101.7 million , which includes net product sales of $58.9 million and contract revenues from collaborations of $42.7 m...

2025-08-05 10:00:00 ET Major earnings expected after the bell on Tuesday include: Advanced Micro Devices ( AMD ) 'Lucid Group ( LCID ) Amgen ( AMGN ) Devon Energy Corporation ( DVN ) Snap ( SNAP ) Read the full article on Seeking Alpha ...

SOPHiA GENETICS SA (SOPH) is expected to report for Q2 2025 Investors Title Company (ITIC) is expected to report for Q2 2025 Safehold Inc. (SAFE) is expected to report $0.39 for Q2 2025 First Guaranty Bancshares Inc. (FGBI) is expected to report $-0.2 for Q2 2025 United Fire Group...

Rigel Pharmaceuticals Inc. (RIGL) is expected to report $1.97 for Q2 2025

Rigel Announces Conference Call and Webcast to Report Second Quarter 2025 Financial Results and Business Update PR Newswire SOUTH SAN FRANCISCO, Calif. , July 29, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will re...

2025-07-20 15:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) PR Newswire SOUTH SAN FRANCISCO, Calif. , July 7, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pur...

2025-06-19 06:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2025-06-10 15:19:33 ET Shares of cancer therapy concern Nuvation Bio, Inc. ( NUVB ) are down over 75% since their debut in 2021 as none of the biotech’s initial lineup of therapies made it past Phase 1 evaluation. Its 2024 purchase of AnHeart has provided it with a NSCLC ...

Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress PR Newswire Final data from the GAVRETO ® (pralsetinib) Phase 1/2 ARROW study in RET fusion-positive NSCLC and other solid tumors Supportive data for REZLIDHI...